Logo 1 Logo 2

Clinical Trial Details

Trial ID: L3847
Source ID: NCT03849495
Associated Drug: Ckd-370
Title: Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-370 and D745 in Healthy Adults
Acronym:
Status: UNKNOWN
Study Results: NO
Results:
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG: CKD-370|DRUG: D745
Outcome Measures: Primary: AUClast of Empagliflozin, Area under the plasma concentration-time curve to last concentration of Empagliflozin, 0 hour ~ 48 hour after drug administration|Cmax of Empagliflozin, Maximum plasma concentration of Empagliflozin, 0 hour ~ 48 hour after drug administration | Secondary: AUCinf of Empagliflozin, Area under the plasma concentration-time curve from zero to infinity concentration of Empagliflozin, 0 hour ~ 48 hour after drug administration|Tmax of Empagliflozin, Time to maximum plasma concentration of Empagliflozin, 0 hour ~ 48 hour after drug administration|T1/2 of Empagliflozin, Half-life of Empagliflozin, 0 hour ~ 48 hour after drug administration|CL/F of Empagliflozin, Apparent clearance of Empagliflozin, 0 hour ~ 48 hour after drug administration|Vd/F of Empagliflozin, Apparent volume of distribution of Empagliflozin, 0 hour ~ 48 hour after drug administration
Sponsor/Collaborators: Sponsor: Chong Kun Dang Pharmaceutical
Gender: ALL
Age: ADULT
Phases: PHASE1
Enrollment: 28
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2019-02-19
Completion Date: 2019-03-21
Results First Posted:
Last Update Posted: 2019-03-12
Locations: Seoul National University Hospital, Seoul, Korea, Republic of
URL: https://clinicaltrials.gov/show/NCT03849495